Attruby (Acoramidis HCl) Patent Expiration, LOE Window & CMS Spending
Attruby (Acoramidis HCl) by BridgeBio Pharma: FDA Orange Book core substance LOE 2038-02-16 (last listed 2039-08-16), 0 AB generics, $870K 2024 CMS Part D & Medicaid spend, and $18,759 CA SB 17 specialty launch WAC.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | BridgeBio Pharma |
| FDA Application & Pathway | N216540 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | 2038-02-16 |
| Last Listed Patent or Exclusivity Date | 2039-08-16 |
| Orange Book Patents (*PED Extensions) | 13 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $870K |
| 2024 Medicare Part D Spend | $870K |
| 2024 Medicaid Spend | $0 |
| Reported Wholesale Price Change (CA SB 17) | Specialty launch notice ($18,759 intro WAC) |